TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
Karo Pharma AS
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
692,566
|
683,137
|
677,353 |
| Financial expenses |
4,393
|
15,985
|
9,784 |
| Earnings before taxes |
181,821
|
159,350
|
133,417 |
| Total assets |
486,988
|
443,782
|
402,851 |
| Current assets |
451,474
|
405,586
|
357,695 |
| Current liabilities |
290,358
|
294,687
|
246,085 |
| Equity capital |
196,631
|
149,095
|
156,766 |
| - share capital |
6,592
|
6,711
|
7,187 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
40.4%
|
33.6%
|
38.9% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
26.3%
|
23.3%
|
19.7% |
| Return on assets (ROA) |
38.2%
|
39.5%
|
35.5% |
| Current ratio |
155.5%
|
137.6%
|
145.4% |
| Return on equity (ROE) |
92.5%
|
106.9%
|
85.1% |
| Change turnover |
21,529
|
50,662
|
144,265 |
| Change turnover % |
3%
|
8%
|
27% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.